NUCB2

General Information

Full gene name:nucleobindin 2 Entrez Gene ID:4925 Location:11p15.1 Synonyms:NEFA Type:protein-coding

User SNPs

SNPs given by the user that are near or inside this gene:

SNP	Distance (bp)	Direction
rs5215	55560	downstream

NCBI Summary

This gene encodes a protein with a suggested role in calcium level maintenance, eating regulation in the hypothalamus, and release of tumor necrosis factor from vascular endothelial cells. This protein binds calcium and has EF-folding domains. [provided by RefSeq, Oct 2011]

OMIM

OMIM ID:`OMIM ID 608020 `_

NCBI Phenotypes

No phenotypes found linked to this gene.

Gene Ontology

• calcium ion binding
• endoplasmic reticulum-Golgi intermediate compartment
• Golgi apparatus
• extracellular space
• cytosol
• protein binding
• DNA binding
• plasma membrane

KEGG Pathways

No pathways found linked to this gene.

GeneRIFs

• Two-hybrid [PMID 15604093]
• polymorphisms in the NUCB2 gene could play an important role in the protection against the development of obesity in male subjects [PMID 21459029]
• Apelins and nesfatin-1 concentrations were higher in mature milk than in colostrum (P<0.05). The concentration of apelins, ghrelins and nesfatin-1 in serum and milk in gestational diabetic lactating women was lower than in control samples [PMID 20813143]
• Plasma nesfatin-1 concentrations were found to be elevated in subjects with both impaired glucose tolerance and newly diagnosed T2 diabetes mellitus. [PMID 22020667]
• structural basis for the properties of Calnuc and NUCB2 binding to Galpha subunits and its regulation by calcium ions. [PMID 21653697]
• Observational study of gene-disease association. (HuGE Navigator) [PMID 19913121]
• nesfatin-1 levels did not differ between hemodialysis patients and healthy subjects and negatively correlated with protein intake [PMID 22036920]
• Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) [PMID 20628086]
• Increased serum prolactin and nesfatin-1 concentrations, decreased ghrelin concentrations could be used as markers to identify patients that have suffered a recent epileptic seizure or other paroxysmal event (psychogenic). [PMID 21554911]
• nucb2 is the direct target gene of AML1 and AML1-ETO, the transcription regulation of AML1, AML1-ETO on nucb2 is carried out via repressing its promoter activity. [PMID 20030931]
• Data report that nesfatin-1 is a novel depot specific adipokine preferentially produced by sc tissue, with obesity- and food deprivation-regulated expression. [PMID 20427481]
• NUCB2 may be implicated in gastric secretion by establishing an agonist-releasable Ca2+ store in ER or Golgi apparatus, signalling via heterotrimeric Galpha proteins and/or mediating the exocytosis of the secretory granules. [PMID 19351608]
• Affinity Capture-MS [PMID 21890473]
• NUCB2 may operate directly at the testicular level to link energy homeostasis, puberty onset, and gonadal function [PMID 22334726]
• High NUCB2 is associated with recurrence and metastasis in breast carcinoma. [PMID 21988594]
• Two-hybrid [PMID 12909641]
• NUCB2-ARTS-1 complexes play an important role in mediating tumor necrosis factor receptor 1 release to the extracellular compartment. [PMID 16407280]
• Calcium-dependent ARTS-1-nucleobindin 2 complexes associate with TNFR1 prior to the commitment of TNFR1 to pathways that result in the constitutive release of TNFR1 exosome-like vesicles or the inducible proteolytic cleavage of TNFR1 ectodomains. [PMID 16407280]
• results suggest that the functions of nucleobindins could be modulated by caspase-mediated cleavage in apoptosis [PMID 18154733]
• Potential weight-reducing actions of nesfatin-1/NUCB-2 treatment. [PMID 21252251]
• low ghrelin and especially the dramatically elevated nesfatin-1 levels might contribute to the pathophyisology of epilepsy[Nesfatin-1] [PMID 19262995]
• Affinity Capture-Western; Reconstituted Complex; Two-hybrid [PMID 10915798]
• lack of nesfatin-1 response to the exercise protocols may be partially due to the fasting condition [PMID 20625762]
• The release of NUCB2 from isolated islets was significantly elevated following glucose challenge. [PMID 20032201]
• Human islet NUCB2 mRNA was reduced in T2D subjects but upregulated after culture in glucolipotoxic conditions. Furthermore, a positive correlation between NUCB2 and glucagon and insulin gene expression, as well as insulin secretory capacity, was evident. [PMID 22108805]

PubMed Articles

Recent articles:

• García-Galiano D et al. “Cellular distribution, regulated expression, and functional role of the anorexigenic peptide, NUCB2/nesfatin-1, in the testis.” Endocrinology. 2012 Apr;153(4):1959-71. PMID 22334726
• Zhang Z et al. “Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus.” Exp Clin Endocrinol Diabetes. 2012 Feb;120(2):91-5. PMID 22020667
• Saldanha JF et al. “The newly identified anorexigenic adipokine nesfatin-1 in hemodialysis patients: Are there associations with food intake, body composition and inflammation?.” Regul Pept. 2012 Jan 10;173(1-3):82-5. PMID 22036920
• Suzuki S et al. “Nucleobindin 2 in human breast carcinoma as a potent prognostic factor.” Cancer Sci. 2012 Jan;103(1):136-43. PMID 21988594
• Riva M et al. “Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects.” Cell Tissue Res. 2011 Dec;346(3):393-405. PMID 22108805
• Wagner SA et al. “A proteome-wide, quantitative survey of in vivo ubiquitylation sites reveals widespread regulatory roles.” Mol Cell Proteomics. 2011 Oct;10(10):M111.013284. PMID 21890473
• Garcia-Marcos M et al. “G Protein binding sites on Calnuc (nucleobindin 1) and NUCB2 (nucleobindin 2) define a new class of G(alpha)i-regulatory motifs.” J Biol Chem. 2011 Aug 12;286(32):28138-49. PMID 21653697
• Zegers D et al. “Association between polymorphisms of the Nesfatin gene, NUCB2, and obesity in men.” Mol Genet Metab. 2011 Jul;103(3):282-6. PMID 21459029
• Aydin S et al. “Time-dependent changes in the serum levels of prolactin, nesfatin-1 and ghrelin as a marker of epileptic attacks young male patients.” Peptides. 2011 Jun;32(6):1276-80. PMID 21554911
• Tan BK et al. “Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment.” J Clin Endocrinol Metab. 2011 Apr;96(4):E669-73. PMID 21252251

Top Pubmed articles linked to gene NUCB2 matching any search term:

• Butler AA et al. “More News About NUCB2/Nesfatin-1: A New Factor in the Hypothalamic Control of Glucose Homeostasis?.” Diabetes. 2012 Aug;61(8):1920-2. PMID 22826310
• Gonzalez R et al. “Nucleobindins: bioactive precursor proteins encoding putative endocrine factors?.” Gen Comp Endocrinol. 2012 May 1;176(3):341-6. PMID 22154814
• Mohan H et al. “Ontogenic pattern of nucleobindin-2/nesfatin-1 expression in the gastroenteropancreatic tissues and serum of Sprague Dawley rats.” Regul Pept. 2012 Apr 10;175(1-3):61-9. PMID 22387700
• Zhang Z et al. “Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus.” Exp Clin Endocrinol Diabetes. 2012 Feb;120(2):91-5. PMID 22020667
• Riva M et al. “Nesfatin-1 stimulates glucagon and insulin secretion and beta cell NUCB2 is reduced in human type 2 diabetic subjects.” Cell Tissue Res. 2011 Dec;346(3):393-405. PMID 22108805
• Stengel A et al. “Minireview: nesfatin-1–an emerging new player in the brain-gut, endocrine, and metabolic axis.” Endocrinology. 2011 Nov;152(11):4033-8. PMID 21862618
• Tan BK et al. “Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans: evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment.” J Clin Endocrinol Metab. 2011 Apr;96(4):E669-73. PMID 21252251
• Gonzalez R et al. “Nesfatin-1 exerts a direct, glucose-dependent insulinotropic action on mouse islet β- and MIN6 cells.” J Endocrinol. 2011 Mar;208(3):R9-R16. PMID 21224288
• Nakata M et al. “Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca(2+) influx through L-type channels in mouse islet β-cells.” Endocr J. 2011;58(4):305-13. PMID 21325742
• Aydin S et al. “The presence of the peptides apelin, ghrelin and nesfatin-1 in the human breast milk, and the lowering of their levels in patients with gestational diabetes mellitus.” Peptides. 2010 Dec;31(12):2236-40. PMID 20813143
• Ghanbari-Niaki A et al. “Plasma nesfatin-1 and glucoregulatory hormone responses to two different anaerobic exercise sessions.” Eur J Appl Physiol. 2010 Nov;110(4):863-8. PMID 20625762
• Bailey SD et al. “Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.” Diabetes Care. 2010 Oct;33(10):2250-3. PMID 20628086
• Stengel A et al. “Nesfatin-1–role as possible new potent regulator of food intake.” Regul Pept. 2010 Aug 9;163(1-3):18-23. PMID 20580651
• Ramanjaneya M et al. “Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity.” Endocrinology. 2010 Jul;151(7):3169-80. PMID 20427481
• Yamada M et al. “Troglitazone, a ligand of peroxisome proliferator-activated receptor-{gamma}, stabilizes NUCB2 (Nesfatin) mRNA by activating the ERK1/2 pathway: isolation and characterization of the human NUCB2 gene.” Endocrinology. 2010 Jun;151(6):2494-503. PMID 20427483
• Foo KS et al. “Nucleobindin-2/nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state.” J Endocrinol. 2010 Mar;204(3):255-63. PMID 20032201